5000th patient treated with protons for eye tumours
From the patient's perspective at the treatment station: The proton beam is directed through the hole in the shield onto the tumour in the eye. The brass shield is adjusted to the individual tumour size and protects the surrounding tissue. © HZB/. S. Kodalle
The treatment centre for eye tumour therapy in Berlin-Wannsee © HZB/ S. Kodalle
For more than 25 years, Charité – Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have been jointly offering proton radiation therapy for eye tumours. The HZB operates a proton accelerator in Berlin-Wannsee for this purpose, while Charité provides medical care for the patients. The 5000th patient was treated at the beginning of August.
The treatment room and proton accelerator are specially adapted to the requirements for optimal and highly precise treatment of tumours inside the eye and are unique in this combination. The largest group of tumours in the eye is the rare and malignant uveal melanoma, which, as the name suggests, develops in the uvea of the eye.
Proton therapy is used as an effective method of fighting tumours, often as an alternative to removing the eye, with the aim of preserving the eye and its function as much as possible. The protons can be directed very precisely at the tumour, sparing the surrounding healthy tissue. Compared to other radiation methods, proton therapy causes less damage to the cornea, lens, retina and optic nerve in many cases.
8 August 2025 was a special day: it was the day on which the 5000th patient completed their eye tumour treatment. This makes the Berlin experts one of the world's leading centres: together, the two institutions (Charité and HZB) have treated 10 percent of all eye tumours treated with protons worldwide. The cooperation with Charité – Universitätsmedizin Berlin also opens up prospects for the further development of proton therapy in order to carry out even more precise and effective treatments in the future – for the benefit of patients.
- What vibrating molecules might reveal about cell biologyInfrared vibrational spectroscopy at BESSY II can be used to create high-resolution maps of molecules inside live cells and cell organelles in native aqueous environment, according to a new study by a team from HZB and Humboldt University in Berlin. Nano-IR spectroscopy with s-SNOM at the IRIS beamline is now suitable for examining tiny biological samples in liquid medium in the nanometre range and generating infrared images of molecular vibrations with nanometre resolution. It is even possible to obtain 3D information. To test the method, the team grew fibroblasts on a highly transparent SiC membrane and examined them in vivo. This method will provide new insights into cell biology.
- Perovskite solar cells from Germany are competing with China's PV technology - HZB 2025 Technology Transfer AwardPhotovoltaics is the leading technology in the transition to clean energy. However, traditional silicon-based solar technology has reached its efficiency limit. Therefore, a HZB-team has developed a perovskite-based multi-junction cell architecture. For this, Kevin J. Prince and Siddhartha Garud received the Helmholtz-Zentrum Berlin's (HZB) Technology Transfer Prize of 5,000 euros.
- Sasol and HZB deepen collaboration with strategic focus on digitalisationSasol Research & Technology and Helmholtz Zentrum Berlin (HZB) are expanding their partnership into the realm of digitalisation, building on their joint efforts in the CARE-O-SENE project and an Industrial Fellowship launched earlier this year. This new initiative marks a significant step forward in leveraging digital technologies to accelerate catalyst innovation and deepen scientific collaboration.